Yale to launch new Center for the Study of Hypoglycemia with $5 million JDRF award for research

November 13, 2000

Yale School of Medicine recently opened the Juvenile Diabetes Research Foundation (JDRF) Center for the Study of Hypoglycemia at Yale University with a five-year, $5 million JDRF grant. The funds will be used to advance multidisciplinary research into the effects of hypoglycemia--low blood sugar--on the brain and how to prevent it.

In individuals with type 1 diabetes, hypoglycemia can occur with even a careful regimen of blood sugar monitoring and insulin injections. Hypoglycemia can cause confusion, abnormal behavior and seizures. Coma and death can result in extreme cases. Normally, symptoms like lightheadedness or hunger can signal low blood sugar, but a severe episode of hypoglycemia can impede the body's ability to detect the next hypoglycemic episode.

"We are pleased to be spearheading this cutting edge research into hypoglycemia," said David A. Kessler, M.D., Dean, Yale School of Medicine. "Diabetes extracts a high toll on individuals and families, and the JDRF center for the study of hypoglycemia at the Yale will aim to bring new discoveries and treatments to light."

Robert Sherwin, M.D., the C.N.H. Long Professor of Medicine, is director of the new center and in addition to overseeing its operation, will use microdialysis to conduct research on the complex biochemical changes that hypoglycemia causes in the brain.

"Our most accomplished researchers in pediatrics, internal medicine, diagnostic radiology and neurosurgery, among other fields, will be conducting research into the causes and solutions for hypoglycemia," said Sherwin. "Three basic research studies, including mine, will each use a different technology to help move us toward this goal."

Douglas Rothman, director and associate professor, Magnetic Resonance Center, will use nuclear magnetic resonance (NMR) to monitor the effects of hypoglycemia on the brain. NMR is a non-invasive form of imaging that does not include radiation. It produces images that enable scientists to track the way the brain uses glucose and how glucose affects neurotransmission.

The third study will use functional magnetic resonance imaging (fMRI) to monitor the effects of hypoglycemia on the brain. Led by John Gore, professor of diagnostic radiology and applied physics, this study will investigate how hypoglycemia affects different parts of the brain, especially when the brain is performing sensory and cognitive tasks. The fMRI detects changes in the blood flow to particular areas of the brain, and can map different areas of the brain affected by hypoglycemia.

A clinical study conducted by William V. Tamborlane, M.D., professor of pediatrics and director of the Children's Clinical Research Center, and Margaret Grey, professor and associate dean for research, Yale School of Nursing, will evaluate the safety and effectiveness of a new glucose sensor manufactured by MiniMed, Inc. The sensor is used in conjunction with an insulin pump and can accurately monitor blood glucose levels at five-minute intervals for up to three days. This data can then be downloaded for analysis and used to try to prevent hypoglycemia.

"Diabetes is a devastating and unpredictable disease, and insulin is an imperfect form of life support," said Robert Goldstein, M.D., Ph.D., chief scientific officer at the JDRF. "This research should help us discover more information about how the body monitors and regulates blood sugar levels, and also create more efficient ways to prevent hypoglycemia, a frightening and dangerous complication of diabetes."
-end-


Yale University

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.